Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2015.07.039 http://scihub22266oqcxt.onion/10.1016/j.intimp.2015.07.039 C5482421!5482421!26315492     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+Immunopharmacol 2015 ; 28 (2): 1102-5 Nephropedia Template TP {{tp|p=26315492|t=2015. An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model |pdf=|usr=}}{{26315492}} gab.com Text An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26315492 #FOAvip Objective: Pulmonary fibrosis causes high morbidity and mortality in affected individuals. Recently, we showed that parenteral or intratracheal administration of a peptide derived from endostatin, called E4, prevents and ameliorates fibrosis using different models of dermal and pulmonary disease. No marketed orally delivered peptide drugs are currently available for progressive pulmonary fibrosis; however oral delivery of drugs is the preferred route for treating most chronic diseases. Thus, we investigated whether oral administration of E4 peptide exerted anti-fibrotic activity in a murine pulmonary fibrosis model. Methods: Bleomycin (1.2mU/g body weight) was intratracheally administrated to male 6?8-week-old C57BL/6J mice. E4 peptide (20, 10, 5, and 1 ?g/mouse) or scrambled control peptide (20 ?g/mouse) were orally administered on the same day as bleomycin. In some experiments, E4 peptide (10 and 5 ?g/mouse) was orally administered three times on days 0, 3, and 6 post-bleomycin treatment. Lungs were harvested on day 21 for histological analysis and hydroxyproline assay. Results: Histological analysis and hydroxyproline assay revealed that bleomycin successfully induced pulmonary fibrosis, and that 20?g of oral E4 peptide ameliorated the fibrosis. The lower doses of E4 peptide (10, 5, and 1 ?g) were insufficient to exert anti-fibrotic activity when given as a single dose. Multiple doses of E4 peptide efficiently exerted anti-fibrotic activity even at lower doses. Conclusion: E4 peptide shows oral bioavailability and exerts anti-fibrotic activity in a bleomycin-induced pulmonary fibrosis model. We suggest that E4 peptide is a novel oral drug for fibroproliferative disorders. Twit Text FOAVip An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26315492 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26315492 #FOAvip English Wikipedia <ref>{{Cite pmid|26315492}}</ref> An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model #MMPMID26315492 Nishimoto T; Mlakar L; Takihara T; Feghali-Bostwick C Int Immunopharmacol 2015[Oct]; 28 (2): 1102-5 PMID26315492show ga Objective: Pulmonary fibrosis causes high morbidity and mortality in affected individuals. Recently, we showed that parenteral or intratracheal administration of a peptide derived from endostatin, called E4, prevents and ameliorates fibrosis using different models of dermal and pulmonary disease. No marketed orally delivered peptide drugs are currently available for progressive pulmonary fibrosis; however oral delivery of drugs is the preferred route for treating most chronic diseases. Thus, we investigated whether oral administration of E4 peptide exerted anti-fibrotic activity in a murine pulmonary fibrosis model. Methods: Bleomycin (1.2mU/g body weight) was intratracheally administrated to male 6?8-week-old C57BL/6J mice. E4 peptide (20, 10, 5, and 1 ?g/mouse) or scrambled control peptide (20 ?g/mouse) were orally administered on the same day as bleomycin. In some experiments, E4 peptide (10 and 5 ?g/mouse) was orally administered three times on days 0, 3, and 6 post-bleomycin treatment. Lungs were harvested on day 21 for histological analysis and hydroxyproline assay. Results: Histological analysis and hydroxyproline assay revealed that bleomycin successfully induced pulmonary fibrosis, and that 20?g of oral E4 peptide ameliorated the fibrosis. The lower doses of E4 peptide (10, 5, and 1 ?g) were insufficient to exert anti-fibrotic activity when given as a single dose. Multiple doses of E4 peptide efficiently exerted anti-fibrotic activity even at lower doses. Conclusion: E4 peptide shows oral bioavailability and exerts anti-fibrotic activity in a bleomycin-induced pulmonary fibrosis model. We suggest that E4 peptide is a novel oral drug for fibroproliferative disorders. äAn endostatin-derived peptide orally exerts anti-fibrotic activity in (epmc).pdf DeepDyve Pubget Overpricing